Validating a process for contract manufacturing products is a joint effort between the Product Owner and the contract manufacturing organization (CMO). The aim of validation is to prove that the process can manufacture a product according to the specifications set forth.
When comparing validation in a single organization to contract manufacturing, one must keep in mind that validation involves the use of two different control systems. In this case the Product Owner holds the marketing license and is aware of the product, while the CMO is responsible for manufacturing and testing operations. Before the validation process starts, both parties must know their roles. The signing of a validation protocol is not enough to ensure control over the process if there is no clear definition of the technical agreement, process knowledge and approval function.
Generally, the product owner or contract giver is obliged to provide approved product information as well as the process knowledge, including manufacturing instructions, critical quality attributes (CQAs), critical process parameters (CPPs), specifications and known process risks.
The CMO must prove ownership of adequate premises and facilities, essential operatives and trained staff, relevant instructions and technological readiness for production. It is responsible for conducting all agreed manufacturing activities under the pharmaceutical quality system and keeping the manufacturing and control records.
The contract should explicitly define the responsibilities of:
The technology transfer process should involve more than only the master manufacturing formula. The information required should include:
A complete assessment of the technology transfer process should indicate the gaps that need to be bridged before the process is validated. If the receiving site uses different equipment or manufacturing technology, it should be used to check the impact scientifically and through quality risk management.
The assessment of readiness must encompass the qualification of all important utilities and manufacturing equipment as well as the parts of the facility. Equipment should be fit for the process and the product process using proper evidence of installation and operation qualification. The equipment must have gone through calibration, preventive maintenance and cleaning procedures for all relevant computerized systems before production.
The contract manufacturer must ensure that all operations instructions are available and staff performing manufacture, sampling, testing and review have been properly trained. The QC methods applied must be appropriate for the purposes they were developed for and the lab capabilities must be sufficient to implement the sampling and testing plan.
The product owner must analyze all material concerning the outsourced manufacturing process. This includes summaries of qualification, findings of audits, assessment of equipment appropriateness and unclosed CAPAs. It is always better to perform an audit of the site and review the audit report, but it does not substitute the need to examine product-specific readiness for validation.
The validation protocol must specify the aim, scope, batch size, equipment and materials in the production cycle, conditions of production, sampling plan, methods of testing, acceptance criteria and other responsibility and documentation requirements. The process parameters and quality characteristics to be controlled should be identified. The justification for controls should be provided.
When it comes to determining the number of validation batches, one must take into account the overall process knowledge, risk, process complexity and variability along with relevant regulatory expectations. Conventionally, three consecutive batches are being used, however, it should not be considered an absolute and unchangeable rule depending on a product and a process. This can also be seen as an approach which needs to be scientifically justified and compliant with relevant requirements.
If the CMO had previously produced a similar product in the past, their experience can be useful in risk evaluation based on it. However, one has to provide evidence that the products are similar in fact rather than just assume it. Differences in formulation, equipment design and batch size, character of raw materials or control processes can be taken into account when choosing the validation strategy.
The production must log the actual processing conditions and all process details : equipment used, batch numbers of raw material, yield, results of in-process tests, interventions made, observations, etc. Quality Control laboratory should do the scheduled tests to ensure that the corresponding analytical data is available. The validation team is to organize the execution and collection of required samples and documents.
The parties must agree on how amendments will be reported in case they occur. For example, if the blending endpoint is not reached within the required limits, the CMO must initiate a deviation process and inform the product owner as stipulated in the quality agreement. The deviation must be evaluated to decide if the batch can be included in the validation study.
The investigation has to ascertain what has happened in which situation, why it happened, which batches or data were involved in the change and how it might affect CQAs and process control as a result. CAPA has to duly pinpoint what has caused the deviation and be proportional to the threat.
Any changes made to the components of a formulation, manufacturing process, equipment, batch size, analytical methodology, or manufacturing location shall be processed through an agreed chain of commands. None of the parties has to assume that changes are acceptable simply because they were approved internally by the one of them.
The technical staff of the CMO must analyze the proofs of manufacturing and testing. Representatives of technical and quality departments of the product's owner must check whether or not the report gives support to its purpose. Responsibilities for approvals must correspond to the agreement and good quality operating procedures.
Validation does not conclude once the report is approved. Continuous verification of the process must be established among the parties along with constant monitoring, periodic reviews and the management of changes. Trends in the process, complaints, deviations in process, yield changes and similar quality issues might require further investigation
During inspections, the authorities may want to know how the manufacturer ensures that the process is under control, how deviations are communicated and whether the manufacturer is able to see the required manufacturing records. The requirements of both companies, obligations of both quarters have to be backed up by proper documents like quality agreements, validation documents, batch records, etc.
The successful validation procedures at the contract manufacturing plant depend on more elements rather than only transferring a production recipe and producing validation batches. The product owner is responsible for sharing sufficient process information and keeping overall control of the process, while CMO has to prepare the site and manage the manufacturing process properly. Product-specific agreements and protocols make it clear for all sides that the process is scientifically valid and helps control manufacturing production afterward.
When comparing validation in a single organization to contract manufacturing, one must keep in mind that validation involves the use of two different control systems. In this case the Product Owner holds the marketing license and is aware of the product, while the CMO is responsible for manufacturing and testing operations. Before the validation process starts, both parties must know their roles. The signing of a validation protocol is not enough to ensure control over the process if there is no clear definition of the technical agreement, process knowledge and approval function.
Establish Responsibility Before Transferring the Process
The first step is to establish the responsibilities of the contract giver and the contract acceptor. The details regarding the responsibilities should be recorded in a quality or technical agreement while ensuring compliance with the GMP.Generally, the product owner or contract giver is obliged to provide approved product information as well as the process knowledge, including manufacturing instructions, critical quality attributes (CQAs), critical process parameters (CPPs), specifications and known process risks.
The CMO must prove ownership of adequate premises and facilities, essential operatives and trained staff, relevant instructions and technological readiness for production. It is responsible for conducting all agreed manufacturing activities under the pharmaceutical quality system and keeping the manufacturing and control records.
The contract should explicitly define the responsibilities of:
- The preparation, technical review and approval and execution of validation protocols.
- Technology transfer and process knowledge transfer.
- Qualification of equipment and utilities in the plant.
- Procurement, qualification, sampling and testing of materials.
- Process validation batch manufacturing and process control.
- Deviation investigation, change control and CAPA.
- Review and approval of validation reports.
- Batch release, record retention and communication with regulatory authorities.
Technology Transfer Must Come Before Validation
Validation of processes should not be regarded as an alternative for an incomplete process of technology transfer. It is important for CMO to have enough knowledge about the product, processes and controls before proceeding with manufacturing validation.The technology transfer process should involve more than only the master manufacturing formula. The information required should include:
- Techniques and detailed instructions.
- Specifications of the raw and packaging materials.
- Critical process parameters (CPPs), critical quality attributes (CQAs) and limits defined by the company.
- Equipment specifications, including any specifications of the most important equipment devices.
- In-production methods and instructions.
A complete assessment of the technology transfer process should indicate the gaps that need to be bridged before the process is validated. If the receiving site uses different equipment or manufacturing technology, it should be used to check the impact scientifically and through quality risk management.
Evaluate Site and Equipment Readiness
Before the production of validation batches begins, make sure the manufacturing site is prepared to perform the process while following normal GMP protocols.The assessment of readiness must encompass the qualification of all important utilities and manufacturing equipment as well as the parts of the facility. Equipment should be fit for the process and the product process using proper evidence of installation and operation qualification. The equipment must have gone through calibration, preventive maintenance and cleaning procedures for all relevant computerized systems before production.
The contract manufacturer must ensure that all operations instructions are available and staff performing manufacture, sampling, testing and review have been properly trained. The QC methods applied must be appropriate for the purposes they were developed for and the lab capabilities must be sufficient to implement the sampling and testing plan.
The product owner must analyze all material concerning the outsourced manufacturing process. This includes summaries of qualification, findings of audits, assessment of equipment appropriateness and unclosed CAPAs. It is always better to perform an audit of the site and review the audit report, but it does not substitute the need to examine product-specific readiness for validation.
Design a Product-Specific Validation Protocol
The validation protocol should show how the process has been transferred and the location of production. The protocol must not be a copy of protocols established for another product or of protocols from the initial manufacturer until the differences are evaluated.The validation protocol must specify the aim, scope, batch size, equipment and materials in the production cycle, conditions of production, sampling plan, methods of testing, acceptance criteria and other responsibility and documentation requirements. The process parameters and quality characteristics to be controlled should be identified. The justification for controls should be provided.
When it comes to determining the number of validation batches, one must take into account the overall process knowledge, risk, process complexity and variability along with relevant regulatory expectations. Conventionally, three consecutive batches are being used, however, it should not be considered an absolute and unchangeable rule depending on a product and a process. This can also be seen as an approach which needs to be scientifically justified and compliant with relevant requirements.
If the CMO had previously produced a similar product in the past, their experience can be useful in risk evaluation based on it. However, one has to provide evidence that the products are similar in fact rather than just assume it. Differences in formulation, equipment design and batch size, character of raw materials or control processes can be taken into account when choosing the validation strategy.
Execute Batches Under Controlled Conditions
Each validation batch is to be produced under prescribed methods and conditions representing their normal processing. There should be no unplanned or unauthorized modifications made just to conform to validation requirements.The production must log the actual processing conditions and all process details : equipment used, batch numbers of raw material, yield, results of in-process tests, interventions made, observations, etc. Quality Control laboratory should do the scheduled tests to ensure that the corresponding analytical data is available. The validation team is to organize the execution and collection of required samples and documents.
The parties must agree on how amendments will be reported in case they occur. For example, if the blending endpoint is not reached within the required limits, the CMO must initiate a deviation process and inform the product owner as stipulated in the quality agreement. The deviation must be evaluated to decide if the batch can be included in the validation study.
Manage Deviations and Changes Across Both Organizations
Deviations that occur during validation in contract manufacturing can encompass equipment, substances, workers, process parameters, analytical tests, or other documentation. The CMO has to investigate occurrences as per its quality system whereas the product owner should be provided with ample information to evaluate how a deviation might affect product quality or lead to a consequence of validation.The investigation has to ascertain what has happened in which situation, why it happened, which batches or data were involved in the change and how it might affect CQAs and process control as a result. CAPA has to duly pinpoint what has caused the deviation and be proportional to the threat.
Any changes made to the components of a formulation, manufacturing process, equipment, batch size, analytical methodology, or manufacturing location shall be processed through an agreed chain of commands. None of the parties has to assume that changes are acceptable simply because they were approved internally by the one of them.
Validation Report Review and Oversight Management
The closure document must detail how protocols have been performed and whether or not acceptance criteria have been met. The document must present results of the batch, processing trends and deviations, investigations carried out and limitations of the study. Raw data and documents must be available for the specified parties to review.The technical staff of the CMO must analyze the proofs of manufacturing and testing. Representatives of technical and quality departments of the product's owner must check whether or not the report gives support to its purpose. Responsibilities for approvals must correspond to the agreement and good quality operating procedures.
Validation does not conclude once the report is approved. Continuous verification of the process must be established among the parties along with constant monitoring, periodic reviews and the management of changes. Trends in the process, complaints, deviations in process, yield changes and similar quality issues might require further investigation
During inspections, the authorities may want to know how the manufacturer ensures that the process is under control, how deviations are communicated and whether the manufacturer is able to see the required manufacturing records. The requirements of both companies, obligations of both quarters have to be backed up by proper documents like quality agreements, validation documents, batch records, etc.
Get ready to use editable Validation Protocols in MS-Word FormatView List


No comments:
Post a Comment
Please don't spam. Comments having links would not be published.